Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06098612 · ClinicalTrials.gov registry record · Early Phase 1

PET Imaging Evaluation of [11C]SY08

A Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Early Phase 1
Development phase
40
Enrollment target
1
Study location

NCT06098612: Recruiting Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy, sponsored by Massachusetts General Hospital.

NCT06098612 is a Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06098612, a Early Phase 1 study of Parkinson's Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Early Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.

Primary Outcome

The investigators will use SUV or SUV to evaluate brain uptake

Conditions Studied

Parkinson's Disease Multiple System Atrophy Dementia With Lewy Bodies Healthy (Controls)

Interventions

  • DRUG C11-SY08

Study Locations (1)

Massachusetts

  • MGH - Charlestown

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-05-01
Est. Completion 2027-11
Phase Early Phase 1
Massachusetts General Hospital

2,032 total trials

What NCT06098612 shows while recruiting

NCT06098612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower).

The record links to 4 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which C11-SY08 is the first listed.

NCT06098612 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06098612 about?

NCT06098612 is a clinical study titled "PET Imaging Evaluation of [11C]SY08". The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to...

What is the current status of trial NCT06098612?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2024-05-01. Estimated completion is 2027-11.

What conditions does trial NCT06098612 study?

This clinical trial studies the following conditions: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy (Controls).

What interventions are being tested in trial NCT06098612?

The interventions under investigation include: C11-SY08 (DRUG).

Who is sponsoring clinical trial NCT06098612?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06098612 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06098612's enrollment target sits among peer trials

40 92nd of 158 higher than 63 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06098612

Source: ClinicalTrials.gov NCT06098612, the US trial registry maintained by the National Library of Medicine. NCT06098612 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.